WCG combines Avoca and MCC citing benefits of collaboration

WCG has combined recent acquisition the Avoca Quality Consortium with the Metrics Champion Consortium (MCC), its clinical trial metrics operation.

The Princeton, New Jersey-headquartered CRO announced the move today, describing it as an expansion of WCG Avoca Quality Consortium (AQC).

CEO Donald Deieso said, “We believe that collaboration and knowledge sharing are critical to driving essential quality improvements and ensuring compliance in clinical research, and standardized performance metrics and benchmarking data are key components of this, which is why we've integrated MCC and AQC.

“WCG is making it possible for industry stakeholders to work together to determine how to consistently measure trial performance and improve it based on actionable insights.”

Avoca – which was acquired by WCG in May – is a life sciences consulting firm dedicated to improving quality and compliance in the clinical trials.

The firm provides expertise and industry-leading approaches and technologies that drug industry customer can use to build quality management, inspection readiness and effective oversight systems into existing processes.

MCC, which has operated since 2006, was set up to bring together biopharmaceutical and medical device trial sponsors, CROs, research sites and technology service providers.

Its aim is to develop standardized performance metrics and tools to help CROs and sponsors optimize clinical trial execution.

In addition to providing both organizations’ services, from January 2022 the combined operation will set up a virtual knowledge center that drug companies can access online.

Patricia Leuchten, Founder and CEO of WCG Avoca predicted the new group would help the drug industry optimize the trials process.

“Our combined work will result in a fully integrated, logically organized, comprehensive catalog of clinical trial metrics.

“This will help drive standardization across the industry and, in turn, move us toward greater clarity and efficiency. Ultimately, implementation of improved measurement programs that have a focus on outcomes will lead to higher quality in clinical trial execution across the industry."

Image: Stock Photo Secrets